HS-20093 targets B7-H3 (CD276) on tumor cells, is internalized, and releases a topoisomerase-inhibitor payload that blocks DNA topoisomerase activity to induce apoptosis. DNA topoisomerase I expression alone is not the binding target and does not make cells directly killed by the drug.